Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux disease

• Published in: Alimentary pharmacology & therapeutics Vol. 16; no. 8; pp. 1469 - 1480
• Main Authors: Vakil, N., Rydén‐Bergsten, T., Bergenheim, K.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.08.2002; Blackwell
• Subjects: Biological and medical sciences; Esophagus; Gastroenterology. Liver. Pancreas. Abdomen; Medical sciences; Other diseases. Semiology; Human; Gastroesophageal reflux; Costs; Methodology; Enzyme; Esophageal disease; H; Enzyme inhibitor; Review; K; Antihistaminic; Proton pump inhibitor; Chemotherapy; Treatment; Antisecretory agent; Health economy; Digestive diseases; Hydrolases; exchanging ATPase; Antagonist; Bibliographic review; H2 Histamine receptor
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1046/j.1365-2036.2002.01303.x

Summary Aim : To perform a systematic review of the economic literature on gastro‐oesophageal reflux disease to evaluate (a) the use of patient‐centred effectiveness end‐points, or (b) the use of patient‐centred economic end‐points, and the influence of these end‐points on the outcome of the model. Methods : Three electronic databases (EMBASE, BIOSIS and Medline) were used, together with a manual search of meeting s for relevant articles. The quality of the studies was determined by the Drummond criteria. Results : Our initial search identified 179 articles and a manual search revealed 78 s and articles. A total of 47 studies (36 fully published articles and 11 s) met the seven Drummond criteria for inclusion in our evaluation. Conclusions : This systematic review demonstrates that many of the published economic evaluations available today take the perspective of the third‐party payer and focus on pharmaceutical costs relevant to the third‐party payer. Our study also demonstrates that there are a number of costs of illness determinations, such that pharmaceutical costs account for only a small proportion of the total costs of managing gastro‐oesophageal reflux disease. Future economic analyses should consider an evaluation of the patient's desire for complete symptom relief by including cost–utility assessments or willingness to pay data.